It is also possible that regorafenib inhibits other signaling pathways (such as the fibroblast growth factor receptor 1 pathway) that may contribute to GIST resistance through previously unrecognized compensatory signaling pathways. This evidence concerns the gene FGFR1 and gastrointestinal stromal tumor.